Review
Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine

Helena Chaytow,1,2,4 Kiterie M.E. Faller,1,2,3,4 Yu-Ting Huang,1,2 and Thomas H. Gillingwater1,2,*

1Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK
2Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, UK
3Royal (Dick) School of Veterinary Studies, University of Edinburgh, UK
4These authors contributed equally
*Correspondence: t.gillingwater@ed.ac.uk
https://doi.org/10.1016/j.xcrm.2021.100346

SUMMARY
Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease that, in the most severe cases and when left untreated, leads to death within the first two years of life. Recent therapeutic advances have given hope to families and patients by compensating for the deficiency in survival motor neuron (SMN) protein via gene therapy or other genetic manipulation. However, it is now apparent that none of these therapies will cure SMA alone. In this review, we discuss the three currently licensed therapies for SMA, briefly highlighting their respective advantages and disadvantages, before considering alternative approaches to increasing SMN protein levels. We then explore recent preclinical research that is identifying and targeting dysregulated pathways secondary to, or independent of, SMN deficiency that may provide adjunctive opportunities for SMA. These additional therapies are likely to be key for the development of treatments that are effective across the lifespan of SMA patients.

INTRODUCTION
Spinal muscular atrophy (SMA), a childhood-onset motor neuron disease, has historically been the most frequent genetic cause of infant mortality, although this is likely to change with the recent therapeutic “revolution.” SMA, caused by mutations in the Survival Motor Neuron 1 (SMN1) gene, leads to loss of SMN protein expression. This is partially compensated for by expression from the paralogous gene SMN2, which differs from SMN1 by a single-nucleotide polymorphism in exon 7.2,3 This base change causes exclusion of exon 7 in nearly 90% of SMN2 transcripts, and the truncated unstable protein (SMNΔ7) is quickly degraded.4 The SMN protein is ubiquitously expressed and plays a fundamental role in cell homeostasis through multiple functions, which are still not fully understood.5 It is involved in various cell mechanisms, such as the assembly of the spliceosomal machinery, endocytosis, and protein translation. Because of its diverse roles and ubiquitous expression, loss of SMN can lead to systemic pathology extending beyond the motor neuron, which has to be considered when designing new therapies.6

Within SMA, disease severity varies, at least in part, according to the number of SMN2 copies carried by the patient.7 In SMA type 0/1, the most frequent form with one copy of SMN2, untreated children will never have the muscular strength to sit unassisted, with a life expectancy of around 2 years. As patients carry more SMN2 copies, the severity of the disease decreases up to type 4, characterized by an early-adulthood clinical onset and typically a normal life expectancy.1 However, this natural history of the disease will likely become obsolete as the majority of patients will receive at least one disease-modifying therapy. As a rare example of a monogenetic neurodegenerative disease, SMA research has pioneered gene-targeted therapy with the recent approval of three therapies designed to enhance SMN production. Regardless of this transformation in SMA therapy, it has become apparent that these novel treatments are still not a cure. In this review, we first describe the three approved therapies before detailing alternative strategies aimed at increasing SMN levels. Finally, we discuss other potential targets for drug development.

GENE-TARGETING SMN REPLACEMENT THERAPIES
Currently, three treatments—nusinersen (Spinraza; Biogen), onasemnogene abeparvovec (Zolgensma; Novartis), and risdiplam (Evrysdi; Roche)—are approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (Table 1). Here, we discuss the development of these three drugs in chronological order of licensing as well as ongoing efforts to improve these strategies.

Nusinersen
Since manipulation of the splicing pattern of the SMN2 gene can produce full-length, functional SMN protein, strategies that target splicing regulatory elements and boost exon 7 inclusion...
| Drug/company          | Mechanism of action | Stage of development | Route of administration and protocol | Population targeted by the license | Cost $, Other comments |
|----------------------|---------------------|----------------------|--------------------------------------|-----------------------------------|------------------------|
| **Approved therapy**|                     |                      |                                      |                                   |                        |
| Nusinersen (Spinraza)/Biogen | splicing modifier of SMN2 (antisense oligonucleotide) | approved by the FDA (December 2016) and the EMA (May 2017) | intrathecal administration: 3 loading doses at 14-day interval, 4th loading dose 30 days after the 3rd dose, and maintenance dose every 4 months thereafter | all ages and all types of SMA | up to $125,000 per dose; drug cost for the first year: $750,000 and then $375,000 annually; rebates have been obtained by some countries and organizations, but in most cases, this is not transparent |
|                      |                     |                      |                                      |                                   |                        |
| Onasemnogene abeparovec-xioi (Zolgensma)/Novartis | replacement of SMN1 gene | approved by the FDA (May 2019) and the EMA (conditional approval May 2020) | intravenous injection (single dose) | FDA: treatment of pediatric patients less than 2 years of age with SMA with bi-allelic mutations in the SMN1 gene. EMA: patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene | $2,125,000 (single injection) |
|                      |                     |                      |                                      |                                   |                        |
| Risdiplam (Evrysdi)/Roche | splicing modifier of SMN2 (small molecule) | approved by the FDA (August 2020) and the EMA (March 2021) | oral, once daily | patients 2 months of age and older | up to $340,000 a year (cheaper in younger patient as dosing is weight related) |

(Continued on next page)
have shown great success and were the first SMN replacement therapy to achieve regulatory approval. Exclusion of exon 7 from the SMN2 transcript is regulated by a section of intron 7 termed the intronic splicing silencer N1 (ISS-N1), located immediately downstream of the 5’ splice site for exon 7, and deletion of the ISS-N1 sequence significantly increased exon 7 inclusion.\textsuperscript{15} Manipulation of such regulatory regions by short complementary sequences of synthetic nucleotides is an important therapeutic approach. To determine the most effective target sequence for exon 7 inclusion, multiple antisense oligonucleotides (ASOs) were tested in mice with the sequence shifting along the target by one base at a time.\textsuperscript{16} The strongest sequence (intron 7 position +10-27) was injected as an 18-mer 2’-O-methoxymethyl-modified ASO into a mild mouse model at embryonic, neonatal, and adult stages. SMN protein levels increased, corresponding to an improvement of the SMA phenotype, and early treatment (embryonic or neonatal) gave a stronger phenotypic correction.\textsuperscript{17} The specific ASO-10-27 was able to dramatically improve lifespan, motor function, and muscle physiology by either systemic or intracerebroventricular injection in two severe SMA mouse models.\textsuperscript{18,19} Preclinical studies in mouse models and non-human primates showed good distribution of the ASO throughout the spinal cord and dose-dependent effects on SMN expression following a single intrathecal infusion.\textsuperscript{19,20} Central nervous system (CNS) and systemic delivery of ASOs have to be considered as complementary strategies, since a combined systemic and CNS-directed delivery strategy had the strongest effect on both survival and vascular-related clinical signs in a severe mouse model of SMA.\textsuperscript{21}

Based on this preclinical evidence, clinical trials were initiated and subjects were found to safely tolerate multiple intrathecal injections in phase II, with evidence of improvement of motor function and achievement of motor milestones.\textsuperscript{22} Successful phase III data led to FDA and EMA approval in December 2016 and June 2017, respectively, as the first drug to treat 5q SMA type 1–3 patients (Table 1). Infants treated before 6 months or later, in ENDEAR and CHERISH trials, respectively, showed positive results in terms of motor milestones and event-free survival; hence, both phase III trials were terminated at the interim stage to allow all participants to move onto nusinersen in an open-label study (SHINE).\textsuperscript{23}

The most recent data from clinical trials for nusinersen provide evidence of long-term safety and efficacy across patient groups, with dramatically improved survival and motor function.\textsuperscript{23,24} After approximately three years of treatment, 100% of SMA type 2 patients were able to sit unsupported, with some able to walk with support, while 76% of SMA type 3 patients could walk independently.\textsuperscript{24} Results also suggest that early treatment may maximize efficacy. Those in the NU Notre clinical trial, which treated infants pre-symptomatically before 6 weeks of age for the first dose, had higher motor function at every point of observation after treatment, with the latest data showing 22 of 25 children able to walk independently and none requiring permanent ventilation.\textsuperscript{25} Nusinersen is now available in many countries, with a wider perspective on its efficacy in a range of patient groups,\textsuperscript{26–28} and some evidence that clinical improvement continues after the first year of treatment.\textsuperscript{29} Finally, a recent study assessed the distribution of ASO and the associated SMN

| Drug/company | Mechanism of action | Population targeted by the license | Route of administration and protocol | Other comments |
|-------------|---------------------|-----------------------------------|-------------------------------------|---------------|
| Branaplam/Novartis | splicing modifier of SMN2 (small molecule) | still under development; enrollment in phases I and II completed | oral administration to protocol (NCT02285836) | oral administration would allow for systemic treatment |
| | | | | |
| | | | | |
| | | | | |
| Nusinersen | antisense oligonucleotide | infantile SMA | not yet applicable | not yet applicable |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
increase in the spinal cord of post-mortem samples from infants treated with nusinersen. This study suggests that there is variability in distribution of ASO within the CNS, with a lower concentration in the cranial portion of the spinal cord and in the brain. However, these results need to be put in perspective, considering these patients died in infancy and as such were poor responders to the therapy.

**Onasemnogene abeparvovec**

Since the causative factor of SMA is a monogenic defect leading to the loss of SMN protein, this motor neuron disease is a prime candidate for gene replacement therapy. The idea of using viral vectors to deliver exogenous genes to relevant tissues was expanded to neurodegenerative diseases when it was demonstrated that systemic delivery via intravenous (i.v.) injection of adeno-associated viral vector serotype 9 (AAV9)-based gene transfer can cross the blood-brain barrier (BBB) and efficiently transduce target cells in the CNS, including motor neurons in the spinal cord in mice and non-human primates. Development of the self-complementary AAV9 (scAAV9) vector further improved the efficiency and speed of gene transcription. Using this technique, AAV9-mediated SMN gene expression delivered at postnatal day 1 (P1) significantly improved lifespan and motor symptoms in SMA models. Initial studies also showed that early treatment of SMA mice at P1 generated better outcomes compared with treatment at P5 or P10, highlighting the importance of early intervention in SMA therapy.

These successes led to the initiation of a phase I clinical trial of onasemnogene abeparvovec (previously AVXS-101; onasemnogene hereafter): a recombinant AAV9 viral vector encoding human SMN protein under the control of the cytomegalovirus enhancer/chicken-β-actin hybrid promoter injected i.v. This first trial treated 15 infants, 3 with low dose and 12 with high dose: all 15 patients survived to 20 months without the need for respiratory support, with 11 patients reaching the motor milestone of sitting unassisted and 2 even walking independently. This positive phase I trial and interim data released from the successive phase II/III trial led to FDA approval in 2019 (Table 1). However, systemic administration by i.v. of high-dose AAV9-SMN was found to cause liver dysfunction in non-human primates. Development of the self-complementary AAV9 (scAAV9) vector further improved the efficiency and speed of gene transcription. Using this technique, AAV9-mediated SMN gene expression delivered at postnatal day 1 (P1) significantly improved lifespan and motor symptoms in SMA models.

Initial studies also showed that early treatment of SMA mice at P1 generated better outcomes compared with treatment at P5 or P10, highlighting the importance of early intervention in SMA therapy.

**Risdiplam**

Risdiplam (RG7916), a small-molecule splice modulator, was approved by the FDA in 2020 and the EMA in 2021. Risdiplam acts as an SMN2 splice modulator, directly binding to SMN2 pre-mRNA at two sites, an exon enhancer sequence and the 5′ splicing site of exon 7, stabilizing the ribonucleoprotein complex and competing with hnRNPG binding, thus promoting exon 7 inclusion and full-length SMN protein production. Risdiplam was optimized from RG7800, a splice modulator found to increase full-length SMN2 mRNA 2-fold in healthy adults and SMA patients. However, development of RG7800 was put on hold due to retinal damage in non-human primates. Risdiplam belongs to the SMN-C class of splice modulators: it increased full-length SMN protein in both severe and mild mouse models of SMA, with an increase in survival and improvement of motor phenotypes.

Oral dosing of risdiplam at 3 mg/kg/day for 7 days in non-human primates showed good biodistribution in relevant tissues, while a phase I trial confirmed good tolerance and no evidence of retinal pathology. Recently published results from the phase II/III FIREFISH study determined improved efficacy at the higher tested dose, for which 7 of 17 infants were able to sit independently after 12 months of treatment. A follow-up study is ongoing, focusing exclusively on the long-term effects of the higher dose. Further phase III clinical trials are ongoing, with SUNFISH assessing effectiveness in type 2/3 patients aged 2 to 25 years old (NCT02908685), JEWELFISH investigating the effects of risdiplam in patients previously treated with other SMA therapies (NCT03032172), and RAINBOWFISH studying risdiplam in pre-symptomatic SMA infants under 6 weeks old at first dose (NCT03779334). Extensive ophthalmologic assessment has also been performed in the patients enrolled in the FIREFISH, SUNFISH, and JEWELFISH clinical trials and did not reveal any retinal toxicity.

**Other potential drugs targeting SMN2 splicing**

Methods of increasing SMN expression via splice modulation continue to be researched for improved efficacy. Branaplam was identified using a high-throughput screen for SMN2 exon 7 inclusion and appears to stabilize SMN2 pre-mRNA with splicing factor complexes. Daily administration showed a dose-dependent increase of exon 7 inclusion and SMN protein expression in SMA mice, with an improvement in body weight and lifespan. The first in-human phase I/II trial started in 2015 across trial centers in Europe (NCT02268552) treating SMA patients younger than 6 months old with 2 copies of SMN2 (Table 1). Interestingly, Novartis has announced a finding of reduced huntingtin mRNA (the mutated protein in Huntington’s disease) in SMA patients treated with branaplam, which has formed the basis of the FDA’s Orphan Drug Designation for branaplam in Huntington’s disease, with a phase Ib trial planned in 2021.

In vitro splicing screens on SMN2 have identified several novel small molecules that modulate splicing patterns and improve exon 7 inclusion, including the identification of risdiplam and branaplam. Additional molecules from the screen initially identifying risdiplam continue to be developed to further enhance SMN splicing. Another recently discovered small molecule, TEC-1, with a similar chemical structure to risdiplam, has demonstrated
increased SMN expression, increased lifespan, and improved motor phenotypes in a severe SMA mouse model, with fewer off-target splicing changes than risdiplam.49 Further screens have identified that flunarizine, a calcium channel blocker, can alter splicing events in HeLa cells, including intron retention in SMN.50 This was confirmed in a screen on SMA patient fibroblasts, where flunarizine increased localization of SMN to Cajal bodies and improved the survival of spinal cord motor neurons from SMA mice.50

Alternatively, while nusinersen shows a strong effect on splicing and good biodistribution and pharmacokinetics, it may be possible to improve these outcomes through adjusting the ASO’s target or chemistry. As such, optimization of ASOs targeting SMN2 splicing continues with localization potential target sequences51 and improved chemistries, including cell-penetrating peptides.52

Critical appraisal of current therapies
These three licensed therapies have been at the forefront of the therapeutic “revolution” for SMA. However, there remain some major limitations and concerns. First, nusinersen must be delivered via invasive intrathecal injection multiple times per year. This leads to CNS-specific distribution, meaning that systemic symptoms may not be fully addressed. Onasemnogene is administered i.v., so it will have systemic distribution, but there remains the issue of bioavailability of the AAV9 serotype and the fact that long-term transgene expression is expected to be limited to post-mitotic cells such as neurons. Conversely, risdiplam is a systemic therapy and is the least invasive licensed treatment with daily oral administration. However, as risdiplam targets the splicing machinery, it may also affect other transcripts, leading to unknown off-target side effects. For example, although risdiplam appears to have very high specificity to SMN2, the cell division regulator FOXM1 is also targeted by risdiplam at high concentrations, risking oncogenic side effects,49 so dosage has been strictly monitored in clinical trials. The long-term effects of all three licensed therapies are currently unknown and may only become apparent many years after onset of treatment. As it stands, through necessity, most available clinical treatment with daily oral administration. However, as risdiplam targets the splicing machinery, it may also affect other transcripts, leading to unknown off-target side effects. For example, although risdiplam appears to have very high specificity to SMN2, the cell division regulator FOXM1 is also targeted by risdiplam at high concentrations, risking oncogenic side effects,49 so dosage has been strictly monitored in clinical trials. The long-term effects of all three licensed therapies are currently unknown and may only become apparent many years after onset of treatment. As it stands, through necessity, most available clinical trials and real-world data highlight the need for adjunctive therapies in order to improve the quality of life of these patients. Research has therefore focused on addressing the systemic consequences of SMN loss. As such, the potential targets are not specific to SMA, but rather fit in a wider strategy for treatment of neuromuscular disorders. A drug that is already approved or in clinical trials for one condition may also be advantageous in SMA, in combination with SMN replacement therapies or alone. This repurposing approach could result in a faster path to the patient due to already available safety profiles. In the following section, we discuss these broader strategies and highlight those that are already in the clinic for various conditions in Table 2.

Non-specific therapies increasing SMN levels
Prior to the development of gene-targeting SMN replacement therapies, multiple approaches have been sought to increase SMN levels using drugs not specifically targeting the SMN gene. Although in the current landscape these drugs may seem redundant, they may be considered as an additional therapy to further enhance SMN expression.

HDAC inhibitors
Histone deacetylase (HDAC) inhibitors have been investigated in SMA models since the early discovery that histone acetylation controls SMN expression.67-69 Multiple HDAC inhibitors are either currently licensed or in clinical trials for cancer treatments (Table 2); hence, they make attractive therapies for alternative indications due to their known safety profiles. Screening HDAC inhibitors in SMA patient-derived neuronal cells showed that targeting class I HDACs in particular could boost SMN expression.70 Valproic acid is a classic class I HDAC inhibitor that has shown beneficial effects in mouse models of SMA1 and patient fibroblasts,69 so it was quickly moved in to clinical trials. A systematic review and meta-analysis of valproic acid clinical trials up to 2017 suggested an overall beneficial effect in motor function, but little evidence of change in survival.54 Another class I HDAC inhibitor, phenylbutyrate, showed promising levels of SMN expression elevation in patient fibroblasts, but showed extremely variable outcomes in patients,72 and the clinical trial was prematurely terminated (NCT00439569). Other small molecules with HDAC inhibitor properties include suberoylanilide hydroxamic acid (SAHA73), trichostatin A,74 and resveratrol.75 Although these molecules showed success in laboratory models of SMA, they have not been progressed to the clinic.

HDAC inhibitors alone cannot provide a therapeutic benefit to the same levels as SMN replacement.54 However, they may provide additional neuroprotective support in combination with other SMN-targeting therapies (“SMN+” therapies75). This idea
Table 2. Summary of drugs with repurposing potential in SMA

| Name of molecule | Mechanism of action for treatment of SMA | Licensed (indication) | Clinical trials in SMA | Clinical trials in other neurological/neuromuscular diseases |
|------------------|------------------------------------------|-----------------------|------------------------|---------------------------------------------------------------|
|                  |                                          |                       | Clinical trials number | Phase | Patient group | Results |                        |
|                  |                                          |                       |                       |       |              |         | ALS - NCT0136110 (phase III); completed, no results posted, NCT03204500 (phase II); completed, no results posted |
| Non-specific therapies increasing SMN levels |
| Flunarizine      | splice modulation                        | Y (not in all countries - migraines) | NA                     | NA    |
| Valproic acid    | HDAC inhibitor - increased SMN expression | Y (bipolar disorder, migraine prophylaxis, epilepsy) | meta-analysis of clinical trials up to 2017 indicated an improvement in motor function, but not survival<sup>54</sup> | ALS - NCT03127514 (phase II); part of combination treatment PB-TURSO, results showing improvement in motor function and survival<sup>56</sup> |
| Sodium phenylbutyrate | HDAC inhibitor - increased SMN expression | Y (urea-cycling disorders) | NCT00528268 I/II Presymp. type 1/2 completed 2015 | ALS - NCT03127514 (phase II); part of combination treatment PB-TURSO, results showing improvement in motor function and survival<sup>56</sup> |
|                   |                                          |                       | NCT00439569 I/II type 2/3 terminated due to poor compliance | IBM - NCT04421677 (phase I); ongoing |
|                   |                                          |                       | NCT00439218 type 1 terminated due to slow recruitment |                |
| SAHA (vorinostat) | HDAC inhibitor - increased SMN expression | Y (lymphoma) | NA | AD - NCT03056495 (phase I): recruiting |
| Resveratrol       | HDAC inhibitor - increased SMN expression | Y (dietary supplement) | NA | ALS - NCT04654689 (phase II); not yet recruiting, muscular dystrophies (phase Ila); improvement in muscle function<sup>56</sup> |
| LBH589 (panobinostat) | HDAC inhibitor - increased SMN expression | Y (myeloma) | NA | NA |
| Azithromycin      | increased SMN expression                 | Y (antibiotic)        | NA | NA |
| Bortezomib        | increased SMN expression                 | Y (myeloma/lymphoma)  | NA | MG - NCT02102594 (phase II); terminated due to low recruitment |
| Neuroprotection   |
| Terazosin         | PGK1 activation                          | Y (hypertension)      | NA | NA |
| OlEsoxime         | mitochondrial protection                 | N                     | 2006-006845-14 Ib type 2/3 well tolerated, no change in motor function | ALS - NCT00868166; NCT01285583 (phase II/III); add-on to riluzole, with no effect on survival or motor function MS - NCT01808885 (phase I); no results posted |
|                   |                                          |                       | NCT01302660 II type 2/3 well tolerated, no change in motor function | |
|                   |                                          |                       | NCT02628743 II type 2/3 long-term motor decline, matched to natural history control data | |
| Riluzole          | glutamate receptor antagonist            | Y (ALS)               | NCT00774423 II/III type 2/3 no results posted | ALS - Cochrane systematic review based on 4 clinical trials suggests that riluzole increases life expectancy by 2–3 months<sup>57</sup> |

(Continued on next page)
| Name of molecule | Mechanism of action for treatment of SMA | Licensed (indication) | Clinical trials in SMA | Clinical trials in other neurological/neuromuscular diseases |
|------------------|----------------------------------------|----------------------|-----------------------|------------------------------------------------------------|
| Gabapentin       | VGCC inhibitor                         | Y (focal seizures and others including muscular symptoms in ALS) | Trial number II/III type 2/3 no effect on any outcome measure improvement in limb strength tests, but no change in respiratory tests | NA |
| Edaravone        | antioxidant                             | Y (ALS - US and Japan only) | NA ALS - NCT00330681 (phase II): no significant functional difference; nevertheless, post hoc analysis suggested it could be effective in patients with shorter disease duration and milder symptoms NCT01492686 (phase III): restricted to patients with shorter disease duration and milder symptoms: slower functional decline in treated patients | |
| Levetiracetam    | anti-epileptic                          | Y (epilepsy)         | NA ALS - NCT00324454 (phase II): no results posted AD - NCT03489044 (phase II): no results posted | |

**Muscle targeting**

| Name of molecule | Mechanism of action for treatment of SMA | Licensed (indication) | Clinical trials in SMA | Clinical trials in other neurological/neuromuscular diseases |
|------------------|----------------------------------------|----------------------|-----------------------|------------------------------------------------------------|
| ACE-031          | ActRII inhibitor                        | N                    | NA DMD - NCT01099761 (phase II): trend toward improved muscular function and increased lean body mass; study discontinued due to side effects (telangiectasia and epistaxis) | |
| Bimagrumab       | ActRII inhibitor                        | N                    | NA sporadic IBM - NCT01925209 (phase IIb): no functional improvement NCT02573467 (phase III): long-term extension of same study (2 years) did not show any functional benefit sarcopenia - NCT02333331 (phase II): no significant functional benefit | |

(Continued on next page)
| Name of molecule | Mechanism of action for treatment of SMA | Licensed (indication) | Clinical trials in SMA | Clinical trials in other neurological/neuromuscular diseases |
|------------------|----------------------------------------|-----------------------|-----------------------|-------------------------------------------------------------|
| Domagrozumab     | myostatin inhibitor                     | N                     | NA                    | DMD - NCT02310763 and NCT02907619 (phase II): no significant functional improvement |
| BIIB110          | ActRIIA/B ligand trap                   | N                     | –                     | no results posted\(^{50}\)                                   |
| Apitegromab (SRK-015) | selective myostatin inhibitor | N                     | NCT03921528           | preliminary results indicate improved HFMSE score           |
| Tirasemtiv (CK-2017357) | FSTAs                                | N                     | NA                    | ALS - NCT02496767 (phase III): no significant difference in the primary outcome measure (SVC) or any secondary outcome measures; poor tolerability |
| Reldesemtiv (CK-2127107) | FSTAs                                 | N                     | NCT02844668           | NA                                                          |
| Somatotropin (somatropin; GH) | anabolic effect | Y (GH deficiency) | NCT00533221           | no significant effect on muscle strength and function       |
| Recombinant IGF-1 (mecasermin) | anabolic effect | Y (growth failure) | NA                    | ALS - Cochrane systematic review showed a slight but significant difference in AALSRS total score (based on 2 clinical trials); the third study included in the meta-analysis did not show any significant difference in muscle strength; the quality of all three clinical trials was low\(^{52}\) |
| BVS857           | IGF-1 mimetic                          | N                     | NA                    | SBMA - NCT02024932 (phase II): significant difference in thigh muscle volume, but no difference in muscle strength and function |

(Continued on next page)
| Name of molecule | Mechanism of action for treatment of SMA | Licensed (indication) | Clinical trials in SMA | Clinical trials in other neurological/neuromuscular diseases |
|------------------|----------------------------------------|----------------------|------------------------|-------------------------------------------------------------|
| Leuprorelin      | gonadotropin releasing hormone (GnRH) analogue | N                    | NA                     | SBMA - UMIN000000474 (phase II): significant delay in functional decline and a decrease in the incidence of pneumonia and death |
| Pyridostigmine   | AChE inhibitor                          | Y (MG)               | NCT02941328 II types 2/3/4 | trial completed, but final results not yet published; preliminary reports show a reduction in fatigability |
| Salbutamol       | [β2-adrenoreceptor agonists](#)          | Y (asthma)           | no large-scale clinical trials | MG - NCT03914638 (phase II/III): recruiting |
| 4-Aminopyridine  | blocking K⁺ channels                    | Y (MS)               | NCT01645787 II/III type 3 | no improvement on motor function (6MWT distance, fatigue) |
| Amifampridine    | blocking K⁺ channels                    | Y (Lambert-Eaton myasthenic syndrome) | NCT03781479 II type 3 | no results posted |
| Fasudil          | ROCK inhibition                          | Y (limited countries only - prevention and treatment of cerebral vasospasm) | NA | ALS - NCT03792490 (phase II): currently recruiting |
| MW150            | p38± MAPK inhibitor                      | N                    | NA | AD - (phase I): ongoing |
| Celecoxib        | NSAID (pain and inflammation)           | Y                    | NCT02876094 II type 2/3 | study terminated; no results posted |

These drugs are either licensed or currently in clinical trials for other indications, but also have a therapeutic effect in preclinical SMA models. With known safety profiles, these therapies could be "repurposed" for SMA and thus have a potentially faster route to the clinic. Information is accurate as of March 2021.

6MWT, 6 minute walk test; AChE, acetylcholinesterase; AD, Alzheimer's disease; FSTA, fast skeletal muscle troponin activator; GH, growth hormone; IBM, inclusion body myositis; MAPK, mitogen-activated protein kinase; MG, myasthenia gravis; MS, multiple sclerosis; PLS, primary lateral sclerosis; presymp., pre-symptomatic; SBMA, spinal-bulbar muscular atrophy; SVC, slow vital capacity; VGCC, voltage-gated calcium channel; Y, yes; N, no; NA, not applicable.
is exemplified in a recent paper showing the benefits of combina-
}
atorial therapy between the HDAC inhibitor LBH589 (panobino-
}
stat) and low doses of Spinraza-like ASOs.77

**R-loops**
During transcription, the double-stranded DNA structure is
broken to allow new RNA transcripts to be created, and the
DNA-RNA structure with the free non-coding DNA strand is
called an R-loop. This physiological process is tightly modulated
by nuclear factors and DNA/RNA-binding proteins. However, R-
loops can be formed, or not resolved properly, under pathologi-
cal conditions, thereby disrupting physiological processes and
leaving the single-stranded DNA more susceptible to degrada-
tion. Suggested mechanisms for pathological R-loop formation
have been mutations in, or up/downregulation of, factors con-

trolling R-loop generation or particularly G-rich DNA sequences.

Since R-loop formation can be governed by splicing factors, and
SMN has a key role in assembly of the spliceosomal small nu-
clear ribonucleoproteins so its loss leads to widespread splicing
defects, these two pathologies may be linked. In cell culture, 
SMN1 knockdown led to increased numbers of R-loops over re-
tained introns, and overexpression of RNase H1 (a factor that
helps resolve R-loops) prevented DNA damage.79 Pathological
R-loop formation is therefore a potential therapeutic target, but
using DNA-binding molecules as therapies comes with an
obvious mutagenic risk. Senataxin, on the other hand, is a
dNA repair factor that co-localizes with SMN in Cajal bodies
and has a decreased expression in SMA models. Overexpression
of senataxin in SMA mouse spinal cord motor neurons re-
duced R-loop formation and DNA damage.79 Another nuclear
factor, zinc-finger protein ZPR1, was also found to have reduced
expression in SMA models.80 Its overexpression doubled the
survival of an intermediate mouse model, improved their righting
reflexes, and increased motor neuron survival and muscle fiber
diameter.80 ZPR1 overexpression was shown to increase
expression of SMN itself, but could clearly have more global pro-
tective pathways as well.

**Stabilizing the SMN protein**
Preventing the degradation of SMNΔ7, the product of SMN2,
thus allowing even low-level expression to have a more pro-
nounced effect on intracellular pathways, could be a therapeutic
strategy. Indopropen is a non-steroidal anti-inflammatory drug
(NSAID) that was identified in an SMN2-luciferase screen to in-
crease SMN protein levels in patient fibroblasts.81 This screen
was also used to identify other compounds that increase SMN
expression in vitro and in vivo.82 A novel aminoglycoside,
TC007, was found to act as a readthrough compound for exon
8 of SMN2, increasing the number of nuclear gems in patient fi-
broblasts,83 and it can slightly increase survival of the severe
SMA mouse model.84 Other readthrough compounds such as
azithromycin have shown some efficacy in mouse models.85

Finally, preventing degradation of SMN using the proteasome
inhibitor bortezomib improved survival and motor outcomes
in SMA mouse models.86 However, none of these approaches
have yet reached clinical trials for SMA (Table 2).

**Neuroprotection**
Since motor neurons are the most severely affected cell type in
SMA, it follows that neuroprotective strategies targeted at this
neuronal population may be effective, in particular when
used in combination with SMN-restoring therapies (SMN+
therapies75).

**Bioenergetics**
Neurons and muscle, the major tissue types affected in SMA,
have particularly high energy demands; thus, targeting energy
pathways may be neuroprotective and therapeutic in SMA. The
glycolytic enzyme phosphoglycerate kinase 1 (PGK1) was found
to be dysregulated in SMA mouse models, and increasing its ac-
tivity pharmacologically with terazosin or its expression geneti-
cally could ameliorate motor axon phenotypes in SMA zebrafish
models.87 Alternatively, olesoxime, a mitochondria-targeting
therapy, was originally shown to promote cell survival under
stressed conditions in vitro, likely via modulation of mitochon-
drial membrane permeability.88 As such, olesoxime could be
broadly applicable across neurodegenerative diseases and
was found to triple the lifespan of the SMA severe mouse
model.88 Olesoxime showed a good safety profile in type 2/3 pa-
tients as well as an improvement in motor function (Table 2).89 It
was therefore moved on to phase III clinical trials, but the trial
was cancelled by Roche amidst the progression of nusinersen,
onasemogene, and risdiplam due to reported issues with
dosage and production. However, due to the current pressing
demand for combinatorial treatments, olesoxime may return as
a subject for future research.90

**Excitotoxicity**
An early strategy in SMA research was to test efficacious drugs
from other neurodegenerative models, particularly amyotrophic
lateral sclerosis (ALS) (Table 2); thus, drugs that target excitotox-
icity have been tested in SMA. Riluzole was used in a small pre-
liminary phase I trial based on its modest effects in ALS, which
gave a suggestion of an effect with a sample size of 7.91 A phase II/III trial to evaluate efficacy of riluzole in SMA patients
was completed in 2013, but no results have been posted
(NCT00774423). Gabapentin is another drug targeting excitotox-
icity that was tested in type 2/3 SMA patients based on its effect
in ALS, showing some effect on motor function in one study,92
but none in another.93 Edaravone, a drug approved for ALS in
the US and Japan, showed some promise in SMA patient-
derived induced pluripotent stem cell (iPSC)-motor neurons,94
but has not yet been taken further. The same group found leve-
tiracetam, an anti-epileptic drug, to have therapeutic potential in
their in vitro SMA model.90

**Muscle-targeting therapies**
Intrinsic and denervation-induced muscle pathology plays an
important role in SMA. This was recently confirmed by an elegant
study where selective depletion of SMN in skeletal muscle of
mice was enough to induce muscular and neuromuscular junc-
tion (NMJ) pathology.94 It has also been hypothesized that
improving muscle pathology could lead to preservation of propr-
icceptive synapses onto motor neurons that are lost in SMA.95
Therefore, muscle is considered a promising therapeutic target
via numerous strategies: myostatin inhibition, activating fast
troponin complexes, modulating metabolic and ergogenic path-
ways, and enhancing mitochondrial function (Figure 1).

Myostatin is a negative regulator of muscle growth, and inhibi-
tion of the myostatin signaling pathway has shown promising
Fast skeletal muscle troponin activators prolong calcium binding to the troponin complex of fast skeletal muscle, hence increasing muscle contractility and reducing the energetic cost of contraction.\textsuperscript{107} This target is the basis of numerous small molecules being developed by Cytokinetics. Unfortunately, the results of a phase II study in SMA type 2–4 patients treated with riluzem (CK-2127107) were not promising; of the 10 primary outcomes, only an improvement in maximum expiratory pressure was observed (NCT02644668).

Another approach is modulation of systemic anabolic pathways as an ergogenic strategy. For example, insulin growth factor-1 (IGF-1) has an anabolic effect on various tissues, including the CNS and muscle, and there is some evidence that enhancing IGF-1 signaling could be beneficial in SMA.\textsuperscript{102} However, a trial in SMA type 2/3 patients treated with synthetic somatotropin (growth hormone, leading to increased IGF-1 expression) did not show any improvement in muscle function.\textsuperscript{103} Similarly, the transcription factor KLF15, regulating metabolic and ergogenic muscular pathways, was downregulated in SMA mouse models, although the first preclinical trials only showed limited effect (Table 2).\textsuperscript{104}

**Targeting the NMJ**

SMA is associated with an impairment of NMJ development, maturation, and function, which contributes to muscle weakness and fatiguability.\textsuperscript{76} In this section, we focus on therapies specifically targeting the NMJ. Other therapeutic strategies can also improve NMJ pathology, e.g., by enhancing cytoskeleton dynamics (see Cytoskeleton section below and Figure 1).

The agrin/MuSK signaling pathway, which plays a key role in the formation and maturation of the NMJ, is dysregulated in SMA. Overexpression of agrin, or its downstream mediators such as DOK7, improves NMJ structure and reduces disease severity in SMA mice.\textsuperscript{105,106} Subcutaneous administration of NT-1654, the active portion of agrin, also delayed SMA mouse disease progression.\textsuperscript{107}

Increased fatigability is a major symptom in SMA type 2/3 patients, and repeated nerve conduction studies show a decrement, confirming that NMJ dysfunction could be playing a key role in fatiguability.\textsuperscript{108} Consequently, a phase II clinical trial\textsuperscript{63} is currently assessing the effects of pyridostigmine, an acetylcholinesterase inhibitor routinely prescribed for myasthenia gravis to slow degradation of acetylcholine within the synaptic cleft, increasing the cholinergic transmission efficiency. Preliminary reports suggested that pyridostigmine reduces fatigability in patients and should be considered as a possible adjunctive therapy (Table 2).\textsuperscript{109}

Salbutamol, a $\beta_2$-adrenoreceptor agonist, modestly improves muscle strength in patients by increasing levels of SMN2 full-length mRNA and protein\textsuperscript{110} and possibly through stabilization of acetylcholine receptor clusters at the NMJ.\textsuperscript{111} Although small clinical studies suggest that it could help maintaining motor function\textsuperscript{63} or improve respiratory function\textsuperscript{112} of SMA type 2 patients, large-scale, placebo-controlled studies are lacking.

Improving neurotransmission at the NMJ is another possible therapeutic strategy. By blocking potassium channels, 4-aminopyridine prolongs the presynaptic action potential and increases acetylcholine release at the NMJ, thereby improving...
neurotransmission and motor function in a Drosophila model of SMA. However, a recent pilot study could not detect any improvement on locomotion in a group of ambulatory adult SMA patients. 114 Amifampridine (3,4-DAP), another aminopyridine approved for the treatment of Lambert-Eaton myasthenic syndrome, has also been evaluated in ambulatory SMA type 3 patients (NCT03781479). Enrollment is complete, but results are yet to be released.

Finally, calcium signaling is also altered in nerve terminals of SMA mice and is associated with decreased neurotransmitter release. 115 By slowing down the closure of the voltage-gated calcium channels, R-roscovitine increases presynaptic calcium influx. 116 This resulted in increased survival and improvement of NMJ morphology in an SMA mouse model.

**Targeting the cytoskeleton**

The cytoskeleton plays a key role in maintaining compartmentalization and polarization of neurons. In SMA, aberrant upregulation of the RhoA/Rho kinase (ROCK) pathway leads to disruption of actin pathways, affecting neuronal growth, differentiation, and regeneration. 117 Pharmacological inhibition of the ROCK pathway by Y-27632 118 and the FDA-approved drug fasudil 119 improved survival, NMJ maturation, and muscle development in an intermediate mouse model of SMA. One of the downstream mediators of the ROCK pathway, PTEN, could be another potential target. 120 Microtubule dynamics is also affected in SMA as stathmin-1, a microtubule-destabilizing protein, is a disease modifier and overexpression improved survival, motor function, and NMJ pathology in an SMA mouse model. 121

**Targeting endocytosis**

There is a growing body of evidence suggesting that perturbation of endocytosis plays an important role in SMA pathophysiology. 122,123 Plastin 3 (PLS3), an actin-bundling protein, 124 and neocalcin delta (NCALD), a neuronal calcium sensor and negative regulator of endocytosis, 125 have been identified as two strong SMN-independent protective modifiers in SMA patients. Overexpressing PLS3 partially rescued motor neuron pathology, especially NMJ structure and function, over a wide range of animal models of SMA, 123,124 although it was insufficient to reverse the pathology in a severe mouse model. 125 Similar therapeutic benefits were obtained by decreasing levels of NCALD. 126 Furthermore, PLS3 interacts with coronin 1C—an actin-bundling protein, with calcineurin-like EF-hand protein 1 (CHP1)—a calcium sensor and calcineurin inhibitor, 127 and with members of the hnRNP F/H family of proteins. 128 Modulation of their respective expression improved impaired endocytic pathways and neuromuscular pathology in SMA models. Considering the overall consistent effect of their modulation on SMA animal models—especially the less severe ones—these represent a particularly attractive target for combinatorial therapy.

**Cell death mechanisms**

**Autophagy, ubiquitin homeostasis, and apoptosis**

Core pathways in cell homeostasis, including autophagy, ubiquitin homeostasis, and apoptotic pathways, have been linked to neurodegeneration in SMA. Autophagy is a finely tuned system as either excessive or insufficient activity can be pathological. In SMA models, autophagosome numbers are increased. 129,130 However, it remains unclear whether autophagic flux is increased or decreased. 129,131 Further studies are warranted as autophagy could represent a therapeutic target. Indeed, administration of 3-methyladenine (an autophagic inhibitor) delayed motor neuron degeneration and subtly increased the lifespan in a severe mouse model. 132 Additionally, calpains, a calcium-dependent family of proteases, regulate numerous cellular processes, including autophagy. Evidence suggests that calpains are overactivated in SMA and inhibition of calpain with calpeptin significantly increased survival and motor activity in SMA mouse models. 132

The other key mechanism for protein degradation is the ubiquitin pathway. Marked dysregulation of this pathway has been shown in SMA, and mutations within one of the only two known E1 ubiquitin-activating enzymes, UBA1, is enough to induce X-linked SMA, a rare disorder with similar clinical symptoms to SMA, but not associated with SMN mutations. 133 Disrupted ubiquitination has been highlighted as a key driver of SMA pathophysiology. A decrease in UBA1 activity is consistently observed across SMA models 134,135 and restoration of UBA1 activity markedly ameliorated the phenotype of zebrafish and mouse models of SMA. 134 This pathway therefore represents a powerful SMN-independent therapeutic target, but future research identifying small molecules that can stabilize or activate UBA1 will be required to facilitate development as an adjunctive therapy. Moreover, SMN itself is degraded via the ubiquitin system and pharmacological inhibition of SMN ubiquitination by ML372, an E3 inhibitor, increased SMN half-life and thus the lifespan of a severe SMA mouse model. 136

The JNK signaling pathway plays a pivotal role in neuronal apoptosis and is a therapeutic target for multiple neurodegenerative disorders. 137 The JNK pathway has been shown to be activated in spinal cord of SMA mice and patients, 138 although a more recent study disputed these findings. 139 Nevertheless, the fact that genetic 138 and pharmacological inhibition 140 of the JNK pathway resulted in improved lifespan and motor function would suggest that this may be a therapeutically relevant pathway in SMA.

**p53 cell death pathway**

Loss of SMN activates the tumor suppressor p53. 141 The p53 pathway therefore presents a potentially attractive therapeutic target, since it is reported to drive motor neuron cell death in a severe mouse model of SMA. 142 Loss of SMN may lead to downstream reduction of the endoplasmic reticulum (ER)-localized transmembrane protein Stasimon, thus activating p53. 142 This same study showed that overexpression of Stasimon was sufficient to block motor neuron degeneration, as mice overexpressing Stasimon showed improved motor function and increased motor neuron numbers. 143 However, the extent to which this rescue is truly SMN independent is unclear, since further analysis of the subset of mice that showed improved motor function also found twice the levels of full-length SMN2 RNA transcripts compared with the non-responding group. 141 Decreased Stasimon expression in SMA models is thought to be due to loss of SMN-mediated U12 intron splicing, and delivery of minor small nuclear RNA (snRNA) genes to boost this splicing pathway improved survival and motor function in SMA mice. 143 This pathway could also be targeted therapeutically via inhibition of
p38 using MW150, thereby preventing phosphorylation and activation of p53. The p38 pathway is also the proposed mechanism of action for celecoxib, an NSAID shown to extend the lifespan of an intermediate mouse model that reached phase II clinical trials, but was recently prematurely terminated with results yet to be published (NCT02876094).

Other potential therapeutic targets

Neurite outgrowth
The transmembrane protein chondrolectin (Chodl), involved in axonal guidance, neurite outgrowth, and synaptogenesis, is dysregulated in SMA. Overexpression of Chodl rescued motor neuron pathology in a zebrafish model. However, further experiments, especially in mammalian models of SMA, are required to confirm the therapeutic potential of this approach.

The cyclin-dependent kinase 5 (CDK5), involved in neuronal architecture maintenance, neurite outgrowth, and synaptic plasticity, is overactivated over a wide range of neurodegenerative disorders, including SMA. Therefore, pharmacological inhibitors of CDK5 could be particularly attractive. In SMA and other neurodegenerative disorders, CDK5 hyperactivity leads to tau hyperphosphorylation. The fact that knocking out tau could ameliorate motor neuron degeneration and synaptic stripping in an SMA mouse model further emphasizes the potential role played by CDK5 and tau in SMA pathophysiology.

miRNAs
Micro-RNAs (miRNAs) are regulatory RNA molecules with diverse and interacting roles in the regulation of the cell’s internal environment and can be either blocked or overexpressed to drive a particular pathway. These strategies are being explored across neurodegenerative diseases. As one example, miR-206 drives regenerative pathways at the NMJ in motor neuron disorders and is upregulated at late stages of disease in SMA mouse models as a pro-survival mechanism, but not sufficiently to rescue motor neuron degeneration. Overexpression of miR-206 extended the lifespan of SMA mice and improved motor performance, suggesting a possible therapeutic option. miR-23a is another potential therapeutic target, since it was found to be downregulated in SMA iPSC-derived motor neurons and overexpression increased the lifespan of SMA mice.

Lifestyle changes
Metabolic dysregulation is common across SMA mouse models and patient groups, incorporating dysregulation of lipids, amino acids, and glucose. As such, modulation of diet and/or exercise may be of significant therapeutic benefit. In a mouse model of mild SMA, both high-intensity swimming and low-intensity running showed benefits in terms of both lipid and glucose metabolism. The therapeutic benefits of exercise would appear to be most applicable to older SMA patients with less severe forms of the disease, or patients with extended survival resulting from treatment with SMN replacement therapies. In particular, lifestyle changes offer a relatively easy (and cheap) way to deliver SMN+ combinatorial therapies.

FUTURE PERSPECTIVES

Over the past few years, the field of SMA research has been revolutionized. Thanks to the development of ground-breaking SMN replacement strategies, there are finally good therapeutic options for families with children diagnosed with SMA, albeit at an extremely high cost. These therapies are completely changing the phenotype of the treated patients, who will no longer follow the natural history of SMA. With a prolonged lifespan and improved neuromuscular function, non-CNS symptoms could become more of a concern in those treated with CNS-targeting therapies. However, regardless of the pioneering nature of these therapies, it is becoming obvious with hindsight and long-term follow-up of the first treated patients that SMN protein replacement is not a cure. The timing of treatment is critical, with early treatment having much better prospects, but there also appears to be a subsection of patients who do not respond. Several factors may contribute to this variable response, including genetic factors beyond SMN1 and SMN2, environmental factors, or access to and quality of medical care. Some patients have already resorted to combining the various available SMN replacement therapies, with no evidence yet for additional benefit, although clinical trials are ongoing and recruiting at the time of writing.

It is now well acknowledged that to improve the chances of a good response to SMN replacement therapy, treatment must be initiated as early in life as possible. The gold standard for SMA treatment should therefore involve neonatal genetic screening, as currently practiced in limited countries in the world. There has even been recent evidence for developmental pathology in utero in SMA mouse models, further highlighting that early treatment is key. The SMA field has been captivated over recent years with the development of these SMN replacement therapies. After a few years of clinical experience, we have seen how life changing these drugs can be, but we are also aware of their limitations, especially for those patients diagnosed later in life or suffering from a milder form of SMA. This calls for SMN+ strategies that include SMN-independent therapies, such as those described in this review. Several of these targets, due to their broadly neuroprotective actions, could also be of benefit to other neurodegenerative disorders, particularly other motor neuron diseases. This cross-disease approach, particularly focusing on repurposing drugs with known safety profiles (Table 2), could drive therapies faster along the path to the patient.

Because of the ubiquitous roles of SMN in the cell, it is not surprising that numerous therapeutic targets are being identified. Animal experiments have shown that a lot of these targets may have more efficacy in milder forms of the disease. This not only advocates for their use as a combinatorial therapy but also calls for a reassessment of previous targets whose effects may have been overlooked when they could not overcome the particularly severe phenotype alone. Currently, the therapeutic potential of most of these targets has been evaluated by genetic manipulation in animal models, and future emphasis should be placed on bridging the gap between target discovery and small-molecule development.

CONCLUSIONS

The three currently approved drugs for SMA replacement therapy have given life-changing treatment options to SMA patients and their families for the first time. All three treatments extend life expectancy and allow patients to reach motor milestones that
would previously have been unachievable. However, the limitations of these therapies are now apparent, opening the road for development of wider targets beyond SMN replacement. Before the efficacy of gene replacement and/or splice modulation was confirmed in clinical trials, alternative SMN-dependent and SMN-independent strategies were investigated. These may still play an important role in SMA therapy, allowing both combinatorial and systemic approaches to be developed. Such approaches targeting pathophysiological events occurring in SMA may also have benefits for other neurodegenerative and neuromuscular diseases. The development of SMN replacement therapies is not the end of the road for SMA therapy development. On the contrary, they have opened a new world of possibilities.

ACKNOWLEDGMENTS

H.C. and Y.-T.H. are funded by the My Name’5 Doddie Foundation (Project Grants). K.M.E.F. is funded by an Academy of Medical Science Starter Grant for Clinical Lecturers.

AUTHOR CONTRIBUTIONS

All authors wrote, edited, and reviewed the manuscript.

DECLARATION OF INTERESTS

T.H.G. has served on SMA advisory boards for Roche.

REFERENCES

1. Verhaart, I.E.C., Robertson, A., Wilson, I.J., Aartsma-Rus, A., Cameron, S., Jones, C.C., Cook, S.F., and Lochmüller, H. (2017). Prevalence, incidence and carrier frequency of Sq-linked spinal muscular atrophy - a literature review. Orphanet J. Rare Dis. 12, 124.
2. Lefebvre, S., Burglen, L., Rebullot, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Milasseau, P., Zeviani, M., et al. (1995). Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165.
3. Monani, U.R., Lorson, C.L., Parsons, D.W., Prior, T.W., Androphy, E.J., Burghes, A.H.M., and McPherson, J.D. (1999). A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8, 1177–1183.
4. Lorson, C.L., and Androphy, E.J. (2000). An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum. Mol. Genet. 9, 259–265.
5. Chaytow, H., Huang, Y.T., Gillingwater, T.H., and Faller, K.M.E. (2018). The role of survival motor neuron protein (SMN) in protein homeostasis. Cell. Mol. Life Sci. 75, 3877–3894.
6. Hamilton, G., and Gillingwater, T.H. (2013). Spinal muscular atrophy: going beyond the motor neuron. Trends Mol. Med. 19, 40–50.
7. Wadman, R.L., Jansen, M.D., Stam, M., Wijngaarde, C.A., Curial, C.A.D., Medic, J., Sooda, P., Schouten, J., Vijzelma, R., Lemmink, H.H., et al. (2020). Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy. Brain Commun. 2, a075.
8. Darrow, J.J., Sharma, M., Shroff, M., and Wagner, A.K. (2020). Efficacy and costs of spinal muscular atrophy drugs. Sci. Transl. Med. 12, 9–12.
9. Hagenacker, T., Wurster, M., Günther, R., Schreiber-Katz, O., Osmanovic, A., Petri, S., Weiler, M., Ziegler, A., Kuller, J., Koch, J.C., et al. (2020). Nusinersen in adults with Sq spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 19, 317–325.
10. Walter, M.C., Wenninger, S., Thiele, S., Stauber, J., Hieber, M., Greckl, E., Stahl, K., Pechmann, A., Lochmüller, H., Kirschner, J., et al. (2019). Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 – A prospective observational study. J. Neuromuscul. Dis. 6, 453–465.
11. Chand, D., Mohr, F., McMillan, H., Tуков, F.F., Montgomery, K., Klein, A., Sun, R., Tauscher-Winiewski, S., Kaufmann, P., and Kullak-Ublick, G. (2021). Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J. Hepatol. 74, 560–566.
12. Sheridan, C. (2020). First oral SMA drug. Nat. Biotechnol. 38, 1111.
13. Roche (2021). Media & Investor Release. https://mi-eu.globenewswire.com/Resource/Download/75a9fb74-7113-47da-aca0-361ca5d6678a.
14. Chamas, L., Voltz, E., Pfister, C., Peters, T., Hartmann, A., Berghs-Clairmont, C., Praestgaard, J., de Raspide, M., Deconinck, N., Born, A., et al. (2017). Safety and efficacy findings in the first-in-human trial (FIH) of the oral splice modulator branaplam in type 1 spinal muscular atrophy (SMA): interim results. Neuromuscul. Disord. 2017, S207–S208.
15. Singh, N.K., Singh, N.N., Androphy, E.J., and Singh, R.N. (2006). Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 26, 1333–1346.
16. Hua, Y., Vickers, T.A., Okunola, H.L., Bennett, C.F., and Krainer, A.R. (2008). Antisense masking of an InRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82, 834–848.
17. Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M.A., Bennett, C.F., and Krainer, A.R. (2010). Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634–1644.
18. Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C.F., and Krainer, A.R. (2011). Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478, 123–126.
19. Passini, M.A., Bu, J., Richards, A.M., Kinnekom, C., Sardi, S.P., Stanek, L.M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011). Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3, 72ra18.
20. Rigo, F., Chun, S.J., Norris, D.A., Hung, G., Lee, S., Matson, J., Fey, R.A., Gaus, H., Hua, Y., Grundy, J.S., et al. (2014). Pharmacology of a central nervous system delivered 2’-O-methoxymethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46–55.
21. Osman, E.Y., Miller, M.R., Robbins, K.L., Lombardi, A.M., Atkinson, A.K., Brehm, A.J., and Lorson, C.L. (2014). Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Hum. Mol. Genet. 23, 4832–4845.
22. Finkel, R.S., Chiriboga, C.A., Vajic, J., Day, J.W., Montes, J., De Vivo, D.C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016). Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017–3026.
23. Finkel, R.S., Mercuri, E., Darras, B.T., Connolly, A.M., Kuntz, N.L., Kirschner, J., Chiriboga, C.A., Saiko, T., Servais, L., Tizzano, E., et al. (2017). Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 377, 1723–1732.
24. Darras, B.T., Chiriboga, C.A., Iannaccone, S.T., Swoboda, K.J., Montes, J., Mignon, L., Xia, S., Bennett, C.F., Bishop, K.M., Shefner, J.M., et al. (2019). Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies. Neurology 92, e2492–e2506.
25. De Vivo, D.C., Bertini, E., Swoboda, K.J., Hwu, W.L., Crawford, T.O., Finkel, R.S., Kirschner, J., Kuntz, N.L., Parsons, J.A., Ryan, M.M., et al. (2019). Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul. Disord. 29, 842–856.
26. Audic, F., de la Banda, M.G.G., Bernoux, D., Ramirez-Garcia, P., Durigneux, J., Barrias, C., Isaop, A., Cuisset, J.M., Cancers, C., Richelme, C., et al. (2020). Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: A French real-life observational study. Orphanet J Rare Dis. 15, 148.

27. Lavie, M., Diamant, N., Cahal, M., Sadot, E., Be‘er, M., Fattal-Valevski, A., Sagi, L., Domany, K.A., and Amirav, I. (2021). Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience. Pediatr. Pulmonol. 56, 291–296.

28. Maggi, L., Bello, L., Bonanno, S., Govoni, A., Caponnetto, C., Passamano, L., Grandis, M., Troisi, F., Cerri, F., Ferraro, M., et al. (2020). Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J. Neurol. Neurosurg. Psychiatry 91, 1166–1174.

29. Pane, M., Coratti, G., Sansone, V.A., Messina, S., Catteruccia, M., Bruno, C., Stramelli, M., Albamonte, E., Pedemonte, M., Amico, A., et al. (2021). Type I SMA “new natural history”: long-term data in nusinersen-treated patients. Ann. Clin. Transl. Neurol. 8, 548–557.

30. Ramos, D.M., d’Ydewalle, C., Gabbeta, V., Dakka, A., Klein, S.K., Norris, D.A., Matson, J., Taylor, S.J., Zaworski, P.G., Prior, T.W., et al. (2019). Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J. Clin. Invest. 129, 4817–4831.

31. Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., et al. (2010). Systemic Delivery of scAAV9 Expressing SMN and motor function in adult spinal muscular atrophy. N. Engl. J. Med. 363, 1747–1757.

32. Meyer, K., Ferraiuolo, L., Schmelzer, L., Braun, L., McGovern, V., Likhite, S., Michels, O., Govoni, A., Fitzgerald, J., Morales, P., et al. (2015). Improving single injection CSF delivery of AV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol. Ther. 23, 477–487.

33. Valori, C.F., Ning, K., Wyles, M., Mclean, A., Parkinson, P., Naryshkin, N.A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K.K.Y., Karp, G.M., Qi, H., Wold, M.G., et al. (2014). SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345, 688–693.

34. Poinier, A., Weetall, M., Heining, K., Bucheli, F., Schoenlein, K., Alsenz, J., Bassett, S., Ullah, M., Senn, C., Ratini, H., et al. (2018). Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol. Res. Perspect. 6, e00447.

35. Sturm, S., Gunther, A., Jaber, B., Jordan, P., Al Kotbi, N., Parkar, N., Cleyry, A., Frances, N., Bergauer, T., Heining, K., et al. (2019). A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br. J. Clin. Pharmacol. 85, 181–193.

36. Baranello, G., Darras, B.T., Day, J.W., Deconinck, N., Klein, A., Masson, R., Mercuri, E., Rose, K., El-Khairi, M., Gerber, M., et al. (2021). Risdiplam in Type 1 Spinal Muscular Atrophy. N. Engl. J. Med. 384, 915–923.

37. Sergott, R.C., Amorelli, G.M., Baranello, G., Barreau, E., Beres, S., Kane, S., Mercuri, E., Orazì, L., SantaMaria, M., Tremolada, G., et al. (2021). Risdiplam treatment has not led to retalitnycity in patients with spinal muscular atrophy. Ann. Clin. Transl. Neurol. 8, 54–65.

38. Palacino, J., Swalley, S.E., Song, C., Cheung, A.K., Shu, L., Zhang, X., Van Hoosier, M., Shin, Y., Chin, D.N., Keller, C.G., et al. (2015). SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat. Chem. Biol. 11, 511–517.

39. Novartis (2020). Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LM1070) in Huntington’s disease (HD). https://www.novartis.com/news/media-releases/novartis-receives-us-food-and-drug-administration-fda-orphan-drug-designation-branaplam-lm1070-huntington%27s-disease-hd.

40. Yousis, I., Berg, M., Kaida, D., Ottmar, J., Wang, C., and Dreyfuss, G. (2010). Rapid-response splicing reporter screens identify differential regulators of constitutive and alternative splicing. Mol. Cell. Biol. 30, 1718–1728.

41. Ando, S., Suzuki, S., Okubo, S., Ohuchi, K., Takahashi, K., Nakamura, S., Shimazawa, M., Fuji, K., and Hara, H. (2020). Discovery of a CNS pene- trant small molecule SMN2 splicing modifier with improved tolerability for spinal muscular atrophy. Sci. Rep. 10, 17472.

42. Sapaly, D., Dos Santos, M., Delers, P., Biondi, O., Que´ rol, G., Houdebine, L., Khoobarry, K., Girardet, F., Burlet, P., Armand, A.S., et al. (2018). Small-molecule fumaronic increases SMN protein in nuclear Cajal bodies and motor function in a moude model of spinal muscular atrophy. Sci. Rep. 8, 2075.

43. Osman, E.Y., Washington, C.W., 3rd, Kafier, K.A., Mazzocateto, C., Patuicci, T.N., Florea, K.M., Simon, M.E., Ko, C.-P., Ebert, A.D., and Lorson, C.L. (2016). Optimization of Morpholino Antisense Oligonucleotides Targeting the Intrinsic Repressor Element1 in Spinal Muscular Atrophy. Mol. Ther. 24, 1592–1601.

44. Hammond, S.M., Hazell, G., Shabanpoor, F., Saleh, A.F., Bowerman, M., Sleigh, J.N., Meijboom, K.E., Zhou, H., Muntoni, F., Talbot, K., et al. (2016). Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 113, 10962–10967.

45. Matesanz, S.E., Battista, V., Flickinger, J., Jones, J.N., and Kilchua, E.A. (2019). Clinical Experience with Gene Therapy in Older Spinal Muscular Atrophy Patients. Pediatr. Neurol. 2021, 1–5.

46. Elshafay, A., Heiu, T.H., Doheim, M.F., Kassem, M.A.M., Eldaodaa, M.F., Holloway, S.K., Abo-Elgheir, H., Hirayama, K., and Huy, N.T. (2019). Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis. CNS Drugs 33, 239–256.
55. Paganoni, S., Hendrix, S., Dickson, S.P., Knowlton, N., Macklin, E.A., Berry, J.D., Elliott, M.A., Maiser, S., Karam, C., Caress, J.B., et al. (2021). Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve 63, 31–39.

56. Kawamura, K., Fukumura, S., Nikaido, K., Tachi, N., Kozuka, N., Seino, T., Hatakeyama, K., Mori, M., Ito, Y.M., Takami, A., et al. (2020). Reverser-atro improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase Ila study. Sci. Rep. 10, 20585.

57. Miller, R.G., Mitchell, J.D., and Moore, D.H. (2012). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2012, CD0011447.

58. Miller, R.G., Moore, D.H., Dronsly, V., Bradley, W., Barohn, R., Bryan, W., Prior, T.W., Gelinas, D.F., Iannaccone, S., Kissel, J., et al. (2001). A placebo-controlled trial of gabapentin in spinal muscular atrophy. J. Neurol. Sci. 191, 127–131.

59. Merlini, L., Solarí, A., Vizza, G., Bertini, E., Minetti, C., Mongini, T., Mazzoni, E., Angelini, C., and Morandi, L. (2003). Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J. Child Neurol. 18, 537–541.

60. Biogen. Pipeline. https://www.biogen.com/en_us/pipeline.html.

61. Rudnicki, S.A., Andrews, J.A., Duong, T., Cockroft, B.M., Malik, F.I., Kawamura, K., Fukumura, S., Nikaido, K., Tachi, N., Kozuka, N., Seino, T., Hatakeyama, K., Mori, M., Ito, Y.M., Takami, A., et al. (2020). Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylation inhibition. Hum. Mol. Genet. 18, 304–317.

62. Miller, R.G., Moore, D.H., Dronsly, V., Bradley, W., Barohn, R., Bryan, W., Prior, T.W., Gelinas, D.F., Iannaccone, S., Kissel, J., et al. (2001). A placebo-controlled trial of gabapentin in spinal muscular atrophy. J. Neurol. Sci. 191, 127–131.

66. Payan, C.A., Hogrel, J.Y., Hammouda, E.H., Lacomblez, L., Ollivier, G., Frongia, A.L., Natera-de Benito, D., Ortez, C., Alarcón, M., Borràs, A., Coratti, G., Forcina, N., Pane, M., and Mercuri, E. (2018). Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? Neuromuscul. Disord. 28, 863–864.

67. Brichard, L., Hofmann, Y., Hahnen, E., Siebbeurnabi, F.A., Raschke, H., Blumcke, I., Eypouy, I.Y., and Wirth, B. (2003). Valproic acid increases SMN levels in spinal muscular atrophy model mice. J. Mol. Med. (Berl.) 66, 1243–1254.

68. Brahe, C., Vitali, T., Tiziano, F.D., Angelozzi, C., Pinto, A.M., Fosco, U., Bertini, E., Mercuri, E., and Neri, G. (2005). Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 13, 256–259.

69. Hauke, J., Riessland, M., Lunke, S., Eyupoglu, I.Y., Blümcke, I., El-Osta, A., Wirth, B., and Hahnen, E. (2009). Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylation inhibition. Hum. Mol. Genet. 18, 304–317.

70. Lai, J.I., Leman, L.J., Ku, S., Vickers, C.J., Olsen, C.A., Montero, A., Ghadirian, M.R., and Gottfels, J.M. (2017). Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy; Screening with iPSC-derived neuronal cells. Bioorg. Med. Chem. Lett. 27, 3289–3293.

71. Tsai, L.K., Tsai, M.S., Ting, C.H., and Li, H. (2008). Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J. Mol. Med. (Berl.) 66, 1243–1254.

72. Brahe, C., Vitali, T., Tiziano, F.D., Angelozzi, C., Pinto, A.M., Fosco, U., Bertini, E., Mercuri, E., and Neri, G. (2005). Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 13, 256–259.

73. Dayanag-Enden, D., Bora, G., Ayhan, P., Kocaefe, C., Dalkara, S., Ye-lexi, K., Demir, A.S., and Erdem-Yurter, H. (2009). Histone deacetylase inhibition activity and molecular docking of (e)-resveratrol: Its therapeutic potential in spinal muscular atrophy. Chem. Biol. Drug Des. 73, 355–364.

74. Groen, E.J.N., Talbot, K., and Gillingwater, T.H. (2018). Advances in therapy for spinal muscular atrophy: promises and challenges. Nat. Rev. Neurool. 14, 214–224.

75. Zhang, J., Fleet, C., Cullen, P., Gupta, S.V., Mekhoubad, S., Chiao, E., Al-laire, N., Bennett, C.F., Rigo, F., Krainer, A.R., et al. (2017). SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage. Proc. Natl. Acad. Sci. USA 114, E2347–E2356.

76. Kannan, A., Bhatia, K., Branceti, D., and Gangwani, L. (2018). Combined deficiency of Senataxin and DNA-PKcs causes DNA damage accumulation and neurodegeneration in spinal muscular atrophy. Nucleic Acids Res. 46, 8326–8346.

77. Kannan, A., Jiang, X., He, L., Ahmad, S., and Gangwani, L. (2020). ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy. Brain 143, 69–93.

78. Mohammad, E.H., Lacomblez, L., Ollivier, G., Doppler, V., Eymard, B., Attarian, S., Pouget, J., Desuelle, C., et al. (2009). Periodic salbutamol tolerability and efficacy in patients with spinal muscular atrophy type I. Neuromuscul. Disord. 29, 517–524.

79. Pera, M.C., Luigetti, M., Sivo, S., Lapenta, L., Granata, G., Antonaci, L., Coratti, G., Forcina, N., Pane, M., and Mercuri, E. (2018). Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? Neuromuscul. Disord. 28, 863–864.

80. Payan, C.A., Hogrel, J.Y., Hammouda, E.H., Lacomblez, L., Ollivier, G., Doppier, V., Eymard, B., Attarian, S., Pouget, J., Desuelle, C., et al. (2009). Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial. Arch. Phys. Med. Rehabil. 90, 1094–1101.

81. Chirita, L., Hofmann, Y., Hahnen, E., Siebbeurnabi, F.A., Raschke, H., Blumcke, I., Eypouy, I.Y., and Wirth, B. (2003). Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 12, 2481–2489.

82. Sumner, C.J., Huynh, T.N., Markowitz, J.A., Perach, J.S., Hill, B., Coov-vert, D.D., Schussler, K., Chen, X., Jarecki, J., Burghes, A.H., et al. (2003). Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54, 647–654.

83. Mattis, V.B., Rai, R., Wang, J., Chang, C.W.T., Coady, T., and Lorson, C.L. (2006). Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum. Genet. 120, 589–601.

84. Mattis, V.B., Tom Chang, C.-W., and Lorson, C.L. (2012). Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy. Neurosci. Lett. 525, 72–75.

85. Osman, E.Y., Washington, C.W., Simon, M.E., Megiddo, D., Greif, H., and Lorson, C.L. (2017). Analysis of Azithromycin Monohydrate as a Single or a Combinatorial Therapy in a Mouse Model of Severe Spinal Muscular Atrophy. J. Neuroimmunol. Dis. 4, 237–249.

86. Foran, E., Kwon, D.Y., Nofziger, J.H., Arnold, E.S., Hall, M.D., Fischbeck, K.H., and Burnett, B.G. (2016). CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol. Dis. 88, 118–124.
87. Boyd, P.J., Tu, W.Y., Shorrock, H.K., Groen, E.J.N., Carter, R.N., Powis, R.A., Thomson, S.R., Thomson, D., Graham, L.C., Motyl, A.A.L., et al. (2017). Bioenergetic state modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. PLoS Genet. 13, e1006744.

88. Bordet, T., Berna, P., Abitbol, J.L., and Pruss, R.M. (2010). Olesoxime (TRO19622): A novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals (Basel) 3, 345–368.

89. Bertini, E., Dessaud, E., Mercuri, E., Muntoni, F., Kirschner, J., Reid, C., Lusakowska, A., Comi, G.P., Cuisset, J.M., Abitbol, J.L., et al. (2017). Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 16, 513–522.

90. Weber, J.J., Clemensson, L.E., Schiödt, H.B., and Nguyen, H.P. (2019). Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate. Biochem. Pharmacol. 168, 305–318.

91. Russman, B.S., Iannaccone, S.T., and Samaha, F.J. (2003). A phase 1 trial of nilozole in spinal muscular atrophy. Arch. Neurol. 60, 1601–1603.

92. Ando, S., Funato, M., Ohuchi, K., Kamayama, T., Inagaki, S., Seki, J., Kawase, C., Tsuruma, K., Shimazawa, M., Kaneko, H., and Hara, H. (2017). Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model. Eur. J. Pharmacol. 847, 161–168.

93. Ando, S., Funato, M., Ohuchi, K., Inagaki, S., Sato, A., Seki, J., Kawase, C., Sato, T., Nishio, H., Nakamura, S., et al. (2019). The Protective Effects of Levetracetam on a Human iPSC-Derived Spinal Muscular Atrophy Model. Neurochem. Res. 44, 1773–1779.

94. Kim, J.-K., Jha, N.N., Feng, Z., Malerba, A., Catapano, F., Sintusek, P., Jarmin, S., Liu, M., Hammers, D.W., Barton, E.R., and Sweeney, H.L. (2016). Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy. PLoS ONE 11, e0166803.

95. Liu, M., Hammers, D.W., Barton, E.R., and Sweeney, H.L. (2016). Activin receptor type IIb inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy. J. Cachexia Sarcopenia Muscle 7, 730–739.

96. Long, K.K., O'Shea, K.M., Howell, K., Paushkin, S., Campbell, C., McMillan, H.J., Mah, J.K., Tanompolsky, M., Selby, K., McClure, T., Wilson, D.M., Sherman, M.L., Escolar, D., and Attie, K.M. (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55, 484–494.

97. Scholar Rock (2000). Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy. https://www.businesswire.com/news/home/20200210200538/en/Scholar-Rock-Announces-Positive-Proof-of-Concept-Data-from-TOPAZ-Phase-2-Trial-Interim-Analysis-of-SRK-015-in-Patients-with-Type-2-and-Type-3-Spinal-Muscular-Atrophy.

98. Cheng, A.J., Hwee, D.T., Kim, L.H., Durham, N., Yang, H.T., Hinken, A.C., Kennedy, A.R., Terjung, R.L., Jasper, J.R., Malik, F.I., and Westerblad, H. (2019). Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction. J. Physiol. 597, 4615–4625.

99. Tsai, L.K., Chen, C.L., Ting, C.H., Lin-Chao, S., Hwu, W.L., Dodge, J.C., Passini, M.A., and Cheng, S.H. (2014). Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice. Mol. Ther. 22, 1450–1459.

100. Kirschner, J., Schorling, D., Hauschke, D., Rensing-Zimmermann, C., Wein, U., Grieben, U., Schottmann, G., Schara, U., Konrad, K., Müller-Felber, W., et al. (2014). Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study. Neuro-muscul. Disord. 24, 134–142.

101. Ahlskog, N., Hayler, D., Krueger, A., Kubinski, S., Claus, P., Hammond, S.M., Wood, M.J.A., Yáñez-Muñoz, R.J., and Bowerman, M. (2019). Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mouse. Gene Ther. 27, 505–515.

102. Kim, J.K., Caine, C., Awano, T., Herbst, R., and Monani, U.R. (2017). Motor neuronal repletion of the NMJ organizer, Agrin, modulates the severity of the spinal muscular atrophy disease phenotype in mouse models. Hum. Mol. Genet. 26, 2377–2385.

103. Kafra, K.A., Villalón, E., Smith, C.E., Simon, M.E., Marquez, J., Hopkins, A.E., Morcos, T.I., and Lorson, C.L. (2020). AAV9-DOK7 gene therapy reduces disease severity in Smnnull SMA model mice. Biochem. Biophys. Res. Commun. 530, 107–114.

104. Boido, M., De Amicis, E., Valsacchi, V., Trevisan, M., Ala, U., Ruegg, M.A., Hettwer, S., and Vercelli, A. (2018). Increasing agrin function antagonizes muscle atrophy and motor impairment in spinal muscular atrophy. Front. Cell. Neurosci. 12, 17.

105. Kim, J.K., Caine, C., Awano, T., Herbst, R., and Monani, U.R. (2017). Motor neuronal repletion of the NMJ organizer, Agrin, modulates the severity of the spinal muscular atrophy disease phenotype in mouse models. Hum. Mol. Genet. 26, 2377–2385.

106. Imlach, W.L., Beck, E.S., Choi, B.J., Lotti, F., Pellizzoni, L., and McCabe, B.D. (2012). SMN is required for sensory-motor circuit function in adult SMA patients. Neuromuscul. Disord. 22, 427–439.

107. Tiwary, A.K., Lin, X., Zhou, J., and Gao, Y. (2019). Synaptotagmin-2, and -1, linked to neurotransmission impairment and motor neuron degeneration in spinal muscular atrophy models of SMA therapeutics: molecular insights. Pharmaceuticals (Basel) 12, 100826.

108. Clausen, L., Cossins, J., and Beeson, D. (2018). Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders. J. Neuromuscul. Dis. 5, 231–240.

109. Khirani, S., Dabdaj, I., Amaddeo, A., Orlino Arroyo, J., Ropers, J., Tirolien, S., Coudert, V., Estoumet, B., Fauroux, B., and Quijano-Roy, S. (2017). Effect of Salbutamol on Respiratory Muscle Strength in Spinal Muscular Atrophy. Pediatr. Neurol. 73, 87–88.e1.

110. Imlach, W.L., Beck, E.S., Choi, B.J., Lotti, F., Pellizzoni, L., and McCabe, B.D. (2012). SMN is required for sensory-motor circuit function in Drosophila. Cell 157, 427–439.

111. Chiriboga, C.A., Marra, J., LaMarca, N.M., Young, S.D., Weimer, L.H., Levin, B., and McCabe, B. (2020). Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients. Neuromuscul. Disord. 30, 693–700.

112. Tejero, R., Lopez-Manzaneda, M., Arumugam, S., and Tabares, L. (2016). Synaptotagmin-2, and -1, linked to neurotransmission impairment and vulnerability in Spinal Muscular Atrophy. Hum. Mol. Genet. 25, 4703–4716.

113. Tejero, R., Falk, S., Franco-Espin, J., Ojeda, J., Hennlein, L., Drexl, H., Dombert, B., Clausen, J.D., Torres-Benito, L., Saal-Bauernschubert, L., et al. (2020). R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy. iScience 23, 100826.
Nölle, A., Zeug, A., van Bergeijk, J., Tönges, L., Gerhard, R., Brinkmann, H., Al Rayes, S., Hensel, N., Schill, Y., Apkhazava, D., et al. (2011). The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. Mol. Hum. Genet. 20, 4865–4878.

Bowerman, M., Beauvais, A., Anderson, C.L., and Kothary, R. (2010). Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 19, 1468–1478.

Bowerman, M., Murray, L.M., Boyer, J.G., Anderson, C.L., and Kothary, R. (2012). Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 10, 24.

Little, D., Valori, C.F., Mutsaers, C.A., Bennett, E.J., Wyles, M., Sharrack, B., Shaw, P.J., Gillingwater, T.H., Azzouz, M., and Ning, K. (2015). PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy. Mol. Ther. 23, 270–277.

Wen, H.-L., Lin, Y.-T., Ting, C.-H., Lin-Chao, S., Li, H., and Hsieh-Li, H.M. (2010). Stathmin, a microtubule-destabilizing protein, is dysregulated in spinal muscular atrophy. Mol. Hum. Genet. 79, 1766–1778.

Hosseinibarkooie, S., Peters, M., Torres-Benito, L., Rastetter, R.H.H., Hupperich, K., Hoffmann, A., Mendoza-Ferreira, N., Kaczmarek, A., Janzen, E., Milbradt, J., et al. (2018). The Power of Human Protective Modifiers: PL33 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype. Am. J. Hum. Genet. 99, 647–665.

Riessland, M., Kaczmarek, A., Schneider, S., Swoboda, K.J., Löhr, H., Bradler, C., Grysko, V., Dimitriadi, M., Hosseinibarkooie, S., Torres-Benito, L., et al. (2017). Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis. Am. J. Hum. Genet. 100, 297–315.

Oprea, G.E., Kröber, S., McWhorter, M.L., Rossoll, W., Müller, S., Krawczak, M., Bassell, G.J., Beattey, C.E., and Wirth, B. (2008). Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320, 524–527.

McGovern, V.L., Massoni-Laporte, A., Wang, X., Le, T.T., Le, H.T., and Hsieh-Li, H.M. (2010). Calpain Inhibition Increases SMN Protein in Spinal Cord Motor Neurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice. Mol. Neurobiol. 46, 4414–4427.

Ramser, J., Ahearn, M.E., Lenski, C., Yariz, K.O., Hellebrand, H., von Rhein, M., Clark, R.D., Schmutzler, R.K., Lichtner, P., Hoffman, E.P., et al. (2008). Rare missense and synonymous variants in UBTEB1 are associated with X-linked infantile spinal muscular atrophy. Am. J. Hum. Genet. 82, 188–193.

Ponis, R.A., Karya, E., Boyd, P., Côme, J., Jones, R.A., Zheng, Y., Sznuyogova, E., Groen, E.J., Hunter, G., Thomson, D., et al. (2016). Systemic restoration of UBAA1 ameliorates disease in spinal muscular atrophy. JCI Insight 1, e87908.

Wishart, T.M., Mutsaers, C.A., Riessland, M., Reimer, M.M., Hunter, G., Hannam, M.L., Eaton, S.L., Fuller, H.R., Roche, S.L., Somers, E., et al. (2014). Disrupted ubiquitin homeostasis and beta-catenin signalling in spinal muscular atrophy. J. Clin. Invest. 124, 1821–1834.

Abera, M.B., Xiao, J., Nozijger, J., Titus, S., Soutiall, N., Zheng, W., Moritz, K.E., Ferrer, M., Cherry, J.J., Androphy, E.J., et al. (2016). ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight 1, e88427.

Musi, C.A., Agro, G., Santarella, F., Iervasi, E., and Borsello, T. (2020). JNK3 as Therapeutic Target and Biomarker in Neurodegenerative and Neurodevelopmental Brain Diseases. Cells 9, 1–22.

Genabai, N.K., Ahmad, S., Zhang, Z., Jian, X., Gabaldon, C.A., and Gangwani, L. (2015). Genetic inhibition of JNK3 ameliorates spinal muscular atrophy. Mol. Hum. Genet. 24, 6986–7004.

Plato, C.M., Park, J.H., Kong, L., d’Ydewalle, C., Valdivia, D., Chen, K.S., Griswold-Prenner, I., and Sumner, C.J. (2019). Motor neuron loss in SMA is not associated with somal stress-activated JNK/C-Jun signalling. Hum. Mol. Genet. 28, 3282–3292.

Schellino, R., Boido, M., Borsello, T., and Vercelli, A. (2018). Pharmacological c-Jun-NH2-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice. Front. Mol. Neurosci. 11, 308.

Simon, C.M., Van Alstyne, M., Lotti, F., Bianchetti, E., Tisdale, S., Watter-son, D.M., Mentis, G.Z., and Pellizzoni, L. (2019). Statin Ameliorates the Loss of Sensory Synapses and Motor Neuron Death in a Mouse Model of Spinal Muscular Atrophy. Cell Rep. 29, 3885–3901.e5.

Simon, C.M., Dai, Y., Van Alstyne, M., Koutsiosampa, C., Pagiatitis, J.G., Chatif, J.J., Wang, X., Rabinowitz, J.E., Henderson, C.E., Pellizzoni, L., et al. (2017). Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Article Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Atrophy. Cell Rep. 21, 3767–3780.

Osman, E.Y., Van Alstyne, M., Yen, P.F., Lotti, F., Feng, Z., Ling, K.K.Y., Ko, C.P., Pellizzoni, L., and Lorson, C.L. (2020). Minor snRNA gene delivery improves the loss of proprioceptive synapses on SMA motor neurons. JCI Insight 5, 130574.

Faroq, F., Abadía-Molina, F., MacKenzie, D., Hadwen, J., Shamin, F., O’Reilly, S., Holcik, M., and MacKenzie, A. (2013). Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Hum. Mol. Genet. 22, 3415–3424.

Steigh, J.N., Barreiro-Iglesias, A., Oliver, P.L., Biba, A., Becker, T., Davies, K.E., Becker, C.G., and Talbot, K. (2014). Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular atrophy. Mol. Hum. Genet. 23, 855–869.

Oprisoreanu, A.M., Smith, H.L., Anya, S., Webster, R., Zhong, Z., Eaton-Hart, C., Wehner, D., Cardozo, M.J., Becker, T., Talbot, K., and Becker, C.G. (2019). Interaction of Axonal Chondrolectin with Collagen XIa Is Necessary for Precise Neuromuscular Junction Formation. Cell Rep. 29, 1082–1098.e10.

Mushtaq, G., Greig, N.H., Anwar, F., Al-Abbasi, F.A., Zamzami, M.A., Al-Taihi, H.A., and Kamal, M.A. (2018). Neuroprotective Mechanisms Mediated by CDK5 Inhibition. Curr. Pharm. Des. 22, 527–534.
148. Miller, N., Feng, Z., Edens, B.M., Yang, B., Shi, H., Sze, C.C., Hong, B.T., Su, S.C., Cantu, J.A., Topczewski, J., et al. (2015). Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy. J. Neurosci. 35, 6038–6050.

149. Valsecchi, V., Boido, M., De Amicis, E., Piras, A., and Vercelli, A. (2015). Expression of muscle-specific MiRNA 206 in the progression of disease in a murine SMA model. PLoS ONE 10, e0128560.

150. Valsecchi, V., Anzilotti, S., Serani, A., Laudati, G., Brancaccio, P., Guida, N., Cuomo, O., Pignataro, G., and Annunziato, L. (2020). miR-206 Reduces the Severity of Motor Neuron Degeneration in the Facial Nuclei of the Brainstem in a Mouse Model of SMA. Mol. Ther. 28, 1154–1166.

151. Kaifer, K.A., Villalon, E., O’Brien, B.S., Sison, S.L., Smith, C.E., Simon, M.E., Marquez, J., O’Day, S., Hopkins, A.E., Neff, R., et al. (2019). AAV9-mediated delivery of miR-23a reduces disease severity in Smn2B/-SMA model mice. Hum. Mol. Genet. 28, 3199–3210.

152. Deguise, M.O., Chehade, L., and Kothary, R. (2021). Metabolic Dysfunction in Spinal Muscular Atrophy. Int. J. Mol. Sci. 22, 5913.

153. Houdebine, L., D’Amico, D., Bastin, J., Chali, F., Dессeille, C., Rumeau, V., Soukari, J., Oudot, C., Rouquet, T., Bariohay, B., et al. (2019). Low-Intensity Running and High-Intensity Swimming Exercises Differentially Improve Energy Metabolism in Mice With Mild Spinal Muscular Atrophy. Front. Physiol. 10, 1258.

154. Dangouloff, T., and Servais, L. (2019). Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives. Ther. Clin. Risk Manag. 15, 1153–1161.

155. Motyl, A.A.L., Faller, K.M.E., Groen, E.J.N., Kline, R.A., Eaton, S.L., Ledahawsky, L.M., Chaytow, H., Lamont, D.J., Wishart, T.M., Huang, Y.T., et al. (2020). Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy. Hum. Mol. Genet. 29, 2674–2683.